Cargando…

COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination

The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wieteska-Miłek, Maria, Szmit, Sebastian, Florczyk, Michał, Kuśmierczyk-Droszcz, Beata, Ryczek, Robert, Kurzyna, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706780/
https://www.ncbi.nlm.nih.gov/pubmed/34960141
http://dx.doi.org/10.3390/vaccines9121395
_version_ 1784622275257958400
author Wieteska-Miłek, Maria
Szmit, Sebastian
Florczyk, Michał
Kuśmierczyk-Droszcz, Beata
Ryczek, Robert
Kurzyna, Marcin
author_facet Wieteska-Miłek, Maria
Szmit, Sebastian
Florczyk, Michał
Kuśmierczyk-Droszcz, Beata
Ryczek, Robert
Kurzyna, Marcin
author_sort Wieteska-Miłek, Maria
collection PubMed
description The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patients. The aim of our cross-sectional study was to identify reasons why PAH/CTEPH patients refused vaccination against COVID-19. Moreover, we assessed the safety profile of approved COVID-19 vaccines in PAH/CTEPH patients. We examined 261 patients (164 PAH patients and 97CTEPH patients) with a median age of 60 (18–92) years, 62% of which were female. Sixty-one patients (23%) refused to be vaccinated. The main reason for unwillingness to be vaccinated was anxiety about adverse events (AEs, 61%). Age and fear of COVID-19 in the univariate analysis and age ≥60 years in the multivariate regression analysis were factors that impacted willingness to be vaccinated (OR = 2.5; p = 0.005). AEs were reported in 61% of vaccinated patients after the first dose and in 40.5% after the second dose (p = 0.01). The most common reported AEs were pain at the injection site (54.5%), fever (22%), fatigue (21%), myalgia (10.5%), and headache (10%). A lower percentage of AEs was reported in older patients (OR = 0.3; p = 0.001). The COVID-19 vaccines are safe for PAH/CTEPH patients. The results obtained in this study may encourage patients of these rare but severe cardio-pulmonary diseases to get vaccinated against COVID-19.
format Online
Article
Text
id pubmed-8706780
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87067802021-12-25 COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination Wieteska-Miłek, Maria Szmit, Sebastian Florczyk, Michał Kuśmierczyk-Droszcz, Beata Ryczek, Robert Kurzyna, Marcin Vaccines (Basel) Article The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patients. The aim of our cross-sectional study was to identify reasons why PAH/CTEPH patients refused vaccination against COVID-19. Moreover, we assessed the safety profile of approved COVID-19 vaccines in PAH/CTEPH patients. We examined 261 patients (164 PAH patients and 97CTEPH patients) with a median age of 60 (18–92) years, 62% of which were female. Sixty-one patients (23%) refused to be vaccinated. The main reason for unwillingness to be vaccinated was anxiety about adverse events (AEs, 61%). Age and fear of COVID-19 in the univariate analysis and age ≥60 years in the multivariate regression analysis were factors that impacted willingness to be vaccinated (OR = 2.5; p = 0.005). AEs were reported in 61% of vaccinated patients after the first dose and in 40.5% after the second dose (p = 0.01). The most common reported AEs were pain at the injection site (54.5%), fever (22%), fatigue (21%), myalgia (10.5%), and headache (10%). A lower percentage of AEs was reported in older patients (OR = 0.3; p = 0.001). The COVID-19 vaccines are safe for PAH/CTEPH patients. The results obtained in this study may encourage patients of these rare but severe cardio-pulmonary diseases to get vaccinated against COVID-19. MDPI 2021-11-25 /pmc/articles/PMC8706780/ /pubmed/34960141 http://dx.doi.org/10.3390/vaccines9121395 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wieteska-Miłek, Maria
Szmit, Sebastian
Florczyk, Michał
Kuśmierczyk-Droszcz, Beata
Ryczek, Robert
Kurzyna, Marcin
COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title_full COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title_fullStr COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title_full_unstemmed COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title_short COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
title_sort covid-19 vaccination in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: safety profile and reasons for opting against vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706780/
https://www.ncbi.nlm.nih.gov/pubmed/34960141
http://dx.doi.org/10.3390/vaccines9121395
work_keys_str_mv AT wieteskamiłekmaria covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination
AT szmitsebastian covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination
AT florczykmichał covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination
AT kusmierczykdroszczbeata covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination
AT ryczekrobert covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination
AT kurzynamarcin covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination